XenikosXenikosXenikosXenikos
  • HOME
  • ABOUT US
    • OUR COMPANY
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • CAREERS
  • T-GUARD®
    • CHARACTERISTICS
    • DEVELOPMENT PLAN
    • GRAFT-VERSUS-HOST
    • ADDITIONAL INDICATIONS
    • EXPANDED ACCESS
    • A PATIENT’S STORY
  • NEWS & EVENTS
    • NEWS
    • EVENTS
    • IN THE MEDIA
    • PUBLICATIONS
  • PARTNERING
    • PARTNERING FOR PROGRESS
  • CONTACT
✕

PUBLICATIONS



Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD
Bone Marrow Transplantation (https://doi.org/10.1038/s41409021-01529-x)
November 23, 2021
Results from an expanded access program of the anti-CD3/CD7 immunotoxin combination (T-Guard) for the treatment of steroid-refractory acute GVHD
ASH Annual Meeting 2019, Orlando
December 19, 2019
Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease
Biol Blood Marrow Transplant 25 (2019) 712-719
October 25, 2019
Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study
International Journal of Pharmaceutics 221 (2001) 175–186
March 30, 2001
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease
Blood • Volume 95, Number 12
June 15, 2000

Xenikos B.V.

Wilhelminasingel 14
6524 AL Nijmegen
The Netherlands
Follow us:

Disclaimer
Website and Clinical Trial Privacy Notice

Contact us

Fill out the contact form
Call us: +31 24 300 01 00
Or send an email: info[at]xenikos.com

Location

©2022 Xenikos B.V. All Rights Reserved. Design: Studio 149